Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2017, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape. Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 7, 1, 5 and 2 respectively. Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology). - The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Venous Leg Ulcers (Crural ulcer) - Overview Venous Leg Ulcers (Crural ulcer) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development CardioVascular BioTherapeutics Inc CytoTools AG Daval International Ltd Factor Therapeutics Ltd FirstString Research Inc GangaGen Inc Hypo-Stream Ltd Leap Therapeutics Inc MediWound Ltd NovaLead Pharma Pvt Ltd Promore Pharma RegeneRx Biopharmaceuticals Inc RMB-Research GmbH Stratatech Corp Venous Leg Ulcers (Crural ulcer) - Drug Profiles Aimspro - Drug Profile Product Description Mechanism Of Action R&D Progress AUP-16 - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile Product Description Mechanism Of Action R&D Progress CODA-001 - Drug Profile Product Description Mechanism Of Action R&D Progress CureXcell - Drug Profile Product Description Mechanism Of Action R&D Progress CVBT-141B - Drug Profile Product Description Mechanism Of Action R&D Progress diperoxochloric acid - Drug Profile Product Description Mechanism Of Action R&D Progress EscharEx - Drug Profile Product Description Mechanism Of Action R&D Progress Granexin - Drug Profile Product Description Mechanism Of Action R&D Progress LL-37 - Drug Profile Product Description Mechanism Of Action R&D Progress NLP-328 - Drug Profile Product Description Mechanism Of Action R&D Progress P-128 - Drug Profile Product Description Mechanism Of Action R&D Progress RGN-137 - Drug Profile Product Description Mechanism Of Action R&D Progress S-42909 - Drug Profile Product Description Mechanism Of Action R&D Progress sodium hypochlorite - Drug Profile Product Description Mechanism Of Action R&D Progress Statmicoll - Drug Profile Product Description Mechanism Of Action R&D Progress VF-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Venous Leg Ulcers (Crural ulcer) - Dormant Projects Venous Leg Ulcers (Crural ulcer) - Discontinued Products Venous Leg Ulcers (Crural ulcer) - Product Development Milestones Featured News & Press Releases Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001) Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment Jun 29, 2015: CytoTools announces positive intermediate results for the European ulcus cruris trial - seamless transition into an approval-relevant phase III trial with less number of patients May 13, 2015: Successful dialogue with the American Food and Drug Administration (FDA) regarding the expansion of the DermaPro clinical trials programme for the indication ulcus cruris in the USA Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Daval International Ltd, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Factor Therapeutics Ltd, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research Inc, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by GangaGen Inc, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Hypo-Stream Ltd, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Leap Therapeutics Inc, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Promore Pharma, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by RMB-Research GmbH, H2 2017 Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corp, H2 2017 Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H2 2017 Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
